title: A replicate designed bioequivalence study to compare two fixed-dose combination products of artesunate and amodiaquine in healthy chinese volunteers.
abstract: Artesun-Plus is a fixed-dose combination antimalarial agent containing artesunate and amodiaquine. The current study was conducted to compare the pharmacokinetic and safety profiles of Artesun-Plus and the WHO-designated comparator product Artesunate Amodiaquine Winthrop. To overcome the high intrasubject variability of artesunate, the study applied a two-sequence and four-period crossover (2 by 4), replicate study design to assess bioequivalence between the two products in 31 healthy male Chinese volunteers under fasting conditions. The results showed that the values of the geometric mean ratios of maximum concentration of drug in plasma (Cmax) and area under the concentration-time curve from time zero to the last blood sample collection (AUC0-last) for the artesunate component in the test and reference products were 95.9% and 93.9%, respectively, and that the corresponding 90% confidence intervals were 84.5% to 108.7% and 87.2% to 101.1%, while the geometric mean ratios for the amodiaquine component in the test and reference products were 95.0% and 100.0%, respectively, and the corresponding 90% confidence intervals were 86.7% to 104.1% and 93.5% to 107.0%. In conclusion, bioequivalence between the two artesunate and amodiaquine fixed-dose combination products was demonstrated for both components. The study also confirmed high intrasubject variability, especially for artesunate: the coefficients of variation (CV) of Cmax values for the test and reference products were 39.2% and 43.7%, respectively, while those for amodiaquine were 30.6% and 30.2%, respectively.
authors: Clinical Research Center, Shanghai Xuhui Central Hospital, Shanghai, China.
authors: Yun
authors: Y
authors: Liu
authors: Clinical Research Center, Shanghai Xuhui Central Hospital, Shanghai, China.
authors: Chaoying
authors: C
authors: Hu
authors: Clinical Research Center, Shanghai Xuhui Central Hospital, Shanghai, China.
authors: Gangyi
authors: G
authors: Liu
authors: Clinical Research Center, Shanghai Xuhui Central Hospital, Shanghai, China.
authors: Jingying
authors: J
authors: Jia
authors: Clinical Research Center, Shanghai Xuhui Central Hospital, Shanghai, China.
authors: Chen
authors: C
authors: Yu
authors: Clinical Research Center, Shanghai Xuhui Central Hospital, Shanghai, China.
authors: Jianmin
authors: J
authors: Zhu
authors: Guilin Pharmaceutical Co., Ltd., Guilin, China.
authors: Qingsi
authors: Q
authors: Zheng
authors: Vivo Development Ltd., Shanghai, China kanyin.zhang@vivodevelopment.com.
authors: Kanyin E
authors: KE
authors: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000655:Amodiaquine / Q000097:blood / Q000493:pharmacokinetics*; D000962:Antimalarials / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D037621:Artemisinins / Q000097:blood / Q000493:pharmacokinetics*; D044466:Asian People; D004338:Drug Combinations; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D008875:Middle Aged; D013810:Therapeutic Equivalency; D055815:Young Adult
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; C515299:amodiaquine, artesunate drug combination; D000655:Amodiaquine